KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBT Margin (2016 - 2025)

Historic EBT Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 861.6%.

  • Xenon Pharmaceuticals' EBT Margin changed N/A to 861.6% in Q1 2025 from the same period last year, while for Sep 2025 it was 4195.93%, marking a year-over-year change of. This contributed to the annual value of 1327.7% for FY2022, which is 8998200.0% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported EBT Margin of 861.6% as of Q1 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' EBT Margin peaked at 228.88% during Q1 2022, and registered a low of 28588.64% during Q3 2022.
  • In the last 3 years, Xenon Pharmaceuticals' EBT Margin had a median value of 766.36% in 2021 and averaged 4736.05%.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' EBT Margin was 1344000bps (2022), while the steepest drop was -282408600bps (2022).
  • Quarter analysis of 3 years shows Xenon Pharmaceuticals' EBT Margin stood at 671.13% in 2021, then crashed by -4160bps to 28588.64% in 2022, then soared by 97bps to 861.6% in 2025.
  • Its last three reported values are 861.6% in Q1 2025, 28588.64% for Q3 2022, and 5820.52% during Q2 2022.